Bristol-Myers Squibb Company (BMY)

BMY (NYSE:Drugs)
$58.80
pos +0.00
+0.00%
Today's Range: 58.66 - 59.50 | BMY Avg Daily Volume: 6,503,700
Last Update: 11/21/14 - 4:05 PM EST
Volume: 0
YTD Performance: 10.63%
Open: $0.00
Previous Close: $58.61
52 Week Range: $46.30 - $59.50
Oustanding Shares: 1,658,776,491
Market Cap: 97,220,890,138
6-Month Chart
TheStreet Ratings Grade for BMY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 9 8 8
Moderate Buy 0 1 1 1
Hold 8 7 8 7
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.18 2.03 2.14 2.09
Latest Dividend: 0.36
Latest Dividend Yield: 2.46%
Dividend Ex-Date: 10/01/14
Price Earnings Ratio: 36.18
Price Earnings Comparisons:
BMY Sector Avg. S&P 500
36.18 36.00 25.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
17.62% 12.32% 93.29%
GROWTH 12 Mo 3 Yr CAGR
Revenue -7.00 -0.16 -0.06
Net Income 3.20 -0.43 -0.17
EPS 32.90 -0.13 -0.05
Earnings for BMY:
EBITDA 3.86B
Revenue 16.39B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $0.40 $0.57 $1.79 $1.78
Number of Analysts 9 2 11 12
High Estimate $0.42 $0.64 $1.81 $2.19
Low Estimate $0.37 $0.50 $1.76 $1.52
Prior Year $0.51 $0.46 $1.82 $1.79
Growth Rate (Year over Year) -21.35% 23.91% -1.55% -0.61%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

bearishBristol-Myers downgraded at Morgan Stanley

Nov 13, 2014 | 7:28 AM EST

BMY downgraded to Equal-weight from Overweight, said Morgan Stanley. Stock is now discounting higher odds of success for new drug in development, creating unbalanced risk-reward dynamic.

By

Jim Cramer

 | Oct 30, 2014 | 12:19 PM EDT

Remember these franchises and who captains them.

By

Christopher Versace

 | Oct 25, 2014 | 12:00 PM EDT

Americans are living much longer these days -- and there are a number of ways to invest.

By

Doug Kass

 | Oct 24, 2014 | 8:07 AM EDT
Where it began.

bullishBristol-Myers upgraded at BMO

Oct 16, 2014 | 8:13 AM EDT

BMY was upgraded to Outperform from Market Perform, BMO Capital said. $55 price target. Consensus expectations are low and have increased confidence in the Nivo lung data. 

By

Jim Cramer

 | Oct 9, 2014 | 4:08 PM EDT

Stop picking on PepsiCo, Allergan and Apple.

bearishBristol-Myers Squibb sell reiterated at MKM

Oct 8, 2014 | 8:16 AM EDT

BMY sell rating reiterated, said MKM. The company announced it will not seek FDA approval for two major drugs, and has withdrawn an additional application. Premium valuation relies on relatively few pipeline programs. Price target of $34.

By

Jim Cramer

 | Oct 8, 2014 | 4:32 AM EDT

In the end, the market will find its feet. 

By

Gary Dvorchak

 | Sep 26, 2014 | 9:00 AM EDT

My strategy for when markets get choppy.

updateBristol-Myers rated new Hold at Deutsche

Aug 27, 2014 | 7:15 AM EDT

BMY was initiated with a Hold rating, Deutsche Bank said. Valuation call, based on a $52 price target. 

Well this is confusing...our models were calling for a run to 2072 before a bearish revers...
Revenue Trend Apple is one of the most remarkable companies in the world, not just becaus...
HOG has topped out. The stock's twelve day winning streak is ending today with and u...
Seems like there was a bid underneath at the crucial 2:45 p.m. hour.. day saver? still not...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.